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RHEUMATOID ARTHRITIS IMPACT OF DISEASE AND DRUG
THERAPY
Franic DM1, Kotzan JA1, Fagan SC1, Grauer DW2
1The University of Georgia, Athens, GA, USA; 2The University of
Kansas, Kansas City, KS, USA
OBJECTIVE: Rheumatoid arthritis (RA) was not considered a
fatal disease, however more recent evidence suggests increased
frequency of cerebrovascular events in RA patients, attributable
to factors beyond those explained in the general population. The
primary purpose of this study is to compare the incidence of new
cerebrovascular events in RA versus non-RA patients using ret-
rospective database accounting for traditional cardiovascular
(CV) risk factors. METHODS: RA patient cohort was identiﬁed
using ICD-9 diagnosis and prescription drug dispensed codes
from the Georgia Medicaid population database from 1999 to
2001. Cerebrovascular events were identiﬁed using ICD-9 codes
for: acute cardiovascular events; other cardiovascular events;
precerebral occlusions; and transischemic attacks (TIAs). A ran-
domized stratiﬁed matched case control analysis of RA versus
non-RA patients was performed based on age, sex, and race.
RESULTS: A sample of 11,842 was included in the study (5921
RA and 5921 non-RA): 44% were white, 80% female and 70%
were aged 21 to 64 years of age. Unadjusted contingency tables
showed the odds of someone having CV, TIA, other CV, and
occlusive disease was 1.58, 2.74, 3.00 and 2.46 times more likely
for a RA than a non-RA patient, respectively. CONCLUSION:
The results of this study supports earlier studies (Ricon et al
2001) showing that RA patients were at greater risk of 
cerebrovascular disease, however, further study is needed to
investigate the etiology. This could be beneﬁcial in designing 
preventative treatment strategies.
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INFLIXIMAB DOSING PATTERNS IN RHEUMATOLOGY
PRACTICES
Hendricks D, Callegari P, Ziskind M
Centocor Inc, Malvern, PA, USA
OBJECTIVES: Inﬂiximab, an antibody that binds to tumor
necrosis factor-alpha (TNF-alpha) is indicated for the treatment
of rheumatoid arthritis (RA). In August 2001, the prescribing
information for inﬂiximab in RA was broadened, allowing both
dose titration (3–10mg/kg) and infusion interval modiﬁcation
(every 4–8 weeks). A retrospective, observational study of inﬂix-
imab dosing patterns in rheumatology practices was conducted
to assess the impact of this label change. METHODS: Rheuma-
tology practices with multiple calls to the inﬂiximab Health Con-
nections Hotline were surveyed and participated (n = 40). Each
practice identiﬁed 3 patients pre-label change (group 1) and 3
patients post-label change (group 2) in a blinded, randomized
fashion. Data on demographics, insurance, diagnosis code, prior
medication use and inﬂiximab infusion history was collected.
RESULTS: Of 249 responses, 206 (82.7%) were evaluated and
analyzed with no statistical differences between groups 1 (n =
98) and 2 (n = 108). The median inﬂiximab dose in the induc-
tion phase and ﬁrst maintenance dose was 3.0mg/kg for both
groups. By maintenance dose 3, the group 1 median dose
remained at 3.0mg/kg while group 2 showed a nonsigniﬁcant
increase to 4.0mg/kg, although both groups reported signiﬁcant
steroid discontinuation. The mean number of vials administered
at this time was 3.2 (group 1) and 3.7 (group 2). The majority
(> 75%) of patients received £5mg/kg every 8 weeks by mainte-
nance dose 3. CONCLUSIONS: Dose ﬂexibility did not signiﬁ-
cantly increase inﬂiximab dose or decrease dosing interval in 
this cohort. The majority of RA patients receive an inﬂiximab
dose of £5mg/kg every 8 weeks with concomitant steroid 
discontinuation.
ARTHRITIS—Cost Studies
PAR3
ECONOMIC EVALUATION OF SELF-INJECTION VS
AMBULATORY CARE OF ANTI-RHEUMATOID BIOLOGICS
(ETANERCEPT) IN JAPAN
Igarashi A1, Fukuda T1,Tsutani K1, Miyasaka N2
1University of Tokyo, Bunkyo,Tokyo, Japan; 2Tokyo Medical and Dental
University,Tokyo, Bunkyo-ku, Japan
OBJECTIVE: To compare economic value of two administration
methods (self-injection and ambulatory care) of anti-rheumatoid
biologics (etanercept) by application of cost-effectiveness analy-
sis (CEA). METHODS: From A societal perspective, we gath-
ered cost data and outcome data. Cost data: 1) direct medical
cost: physician visit fee, injection fee, laboratory test fee, and in-
house self-injection guidance fee (from health insurance fee
schedule), drug costs (hypothetical costs—since etanercept is not
approved by Ministry of Health, Labour and Welfare yet); 2)
direct non-medical cost: transportation cost. Data were gained
from “Rheumatoid tomonokai”, RA patients organization in
Japan and teaching cost of self-injection. To estimate teaching
cost, we conducted a survey to health care provider; AND 3)
indirect cost: productivity loss. Outcome data: ACR20 gained
from 3rd phase of clinical trial data of etanercept in the Japan
and safety issues subject to self-injection, such as delayed ﬁnding
ADR, accidentally impale needles to other people, and so on.
Such data were gained from case report form (CRF). Because we
set the time horizon for analysis as 1 year, we did not apply dis-
count rate. We performed sensitivity analyses on 1) incidence of
ADR; 2) education cost; 3) frequency of hospital visit; AND 4)
productivity loss. RESULT: Effectiveness of self-injection care
and ambulatory care were considered to be similar. Adverse reac-
tion due to self-injection was not reported. Thus, we conducted
cost minimization analysis. Total cost of self-injection group
including indirect costs was JPY2,674,758 ($US22,746), which
was lower than that of ambulatory care group, JPY3,255,110
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